CASP3 and colorectal carcinoma: Preclinical studies have shown that TAM (CD68) can be activated during 5-FU treatment and can give CRC cells against chemotherapy with 5-FU during 5-FU treatment, which may be caused by TAM secreting ornithine decarboxylase (ODC)-dependent decay activation JNK-caspase-3, which further leads to the CRC cells against chemotherapy with 5-FU [55].